CTOs on the Move

American Academy Of Pain Medicine

www.painmed.org

 
American Academy Of Pain Medicine is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.painmed.org
  • 4700 W Lake Ave
    Glenview, IL USA 60025
  • Phone: 847.375.4731

Executives

Name Title Contact Details

Similar Companies

House Research Insitute

House Research Insitute is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Collective Medical

Collective Medical empowers care teams to improve patient outcomes by closing the communication gaps that undermine patient care through seamless collaboration. With a nationwide network engaged with every national health plan in the country, hundreds of hospitals and health systems and tens of thousands of providers—including hospitals, emergency departments, skilled nursing facilities, primary care providers, mental and behavioral health clinics, and others—Collective Medical`s system-agnostic platform is trusted by healthcare organizations and payers to identify at-risk and complex patients and facilitate actionable collaboration to make better care decisions and improve outcomes. Based in Salt Lake City, Collective Medical is proven to streamline transitions of care, improve coordination across diverse care teams, and reduce unnecessary hospital admissions.

intellyst Medical Communications

intellyst Medical Communications is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BCI Healthcare

BCI Healthcare is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.